We performed ChIP-seq on MV4-11 or OCI-AML3 cells which had been treated with DMSO or 5 nM of the FLT3 inhibitor Quizartinib (AC220) to determine the location of ATF4 or RNAPII across the genome. Overall design: Cells were treated with the FLT3 inhibitor Quizartinib (AC220, 5 nM, for 24 hours) prior to cross-linking, isolation and sonication of nuclei and immunoprecipitation of chromatin using antibodies against ATF4 or RNAPII.